Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Do Hedge Funds Think of Sarepta Therapeutics Inc (SRPT)?

In a rather quiet market where the Dow is down but the S&P and NASDAQ are both up, Sarepta Therapeutics Inc (NASDAQ:SRPT) shares have rallied 3%, showing some solid relative strength.

Given the normal volume traded (of 1 million shares at mid-day versus 2.5 million on average), we don’t think that Sarepta Therapeutics is moving on any fundamental news.

At this point, Sarepta Therapeutics Inc (NASDAQ:SRPT) shares look range-bound since late December. Investors are eager for to analyze any Exondys 51 sales data that comes out. Analysts are for the most part bullish with Ritu Baral of Cowen assigning a $62 price target and an ‘Outperform’ rating. Anupam Rama of JPMorgan has a $42 price target, saying that his survey data suggests Exondys 51 sales could come in at $94 million for 2017, versus the $90-$91 million consensus. Judging by the price action, many traders think there is a good probability that Sarepta Therapeutics Inc (NASDAQ:SRPT) will remain range-bound until actual data comes out.

While analysts are for the most part bullish, our data shows that the smart money is more cautious. Of the 742 elite funds we track, 25 funds owned $451.9 million of Sarepta Therapeutics Inc (NASDAQ:SRPT) and accounted for 30.10% of the float on December 31, versus 32 funds and $1.12 billion respectively on September 30. 18% of the stock’s float is also short.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Trade (NASDAQ:SRPT) Now!

Disclosure:None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...